Literature DB >> 9298180

Severity scoring of atopic dermatitis: a comparison of three scoring systems.

A B Sprikkelman1, R A Tupker, H Burgerhof, J P Schouten, P L Brand, H S Heymans, W M van Aalderen.   

Abstract

In studies on atopic dermatitis (AD), different scoring systems are used to evaluate the severity of the disease. The objective of this study was to investigate agreement between observers in the assessment of the overall severity of AD, and interobserver variation in the assessment of severity of AD for each scoring item separately, using the Simple Scoring System (SSS), the Scoring Atopic Dermatitis (SCORAD) index, and the Basic Clinical Scoring System (BCSS), and, furthermore, to investigate agreement between these three scoring systems in the assessment of the overall severity of AD. Eighty-two patients (42 male) with AD, mean age 13.4 years (range 0.2-67.0), were included. Agreement between observers in assessing the overall AD severity scores, and interobserver variation in assessing AD severity of each scoring item separately were determined in 34 of these 82 patients by two physicians scoring the severity of AD by the three scoring systems. To determine agreement between the scoring systems, one physician scored the severity of AD in all patients with the three scoring systems. Agreement between observers and agreement between the three scoring systems was calculated by Cohen's kappa (kappa) and by the measure of agreement according to Bland & Altman. kappa > 0.4 represents fair agreement; kappa > 0.75 excellent agreement. In addition, interobserver variation for each scoring item separately was calculated by the Wilcoxon signed rank test. The mean differences (d) and the limits of agreement (d +/- 2 SD of the differences) between observers by the SSS and the SCORAD were -0.82 +/- 5.58 and -0.28 +/- 7.49, respectively, kappa between observers for the BCSS was 0.90 (95% CI 0.79-1.03). By the SSS, significant interobserver variation was found in assessing the severity of excoriations (P = 0.02) and scales (P = 0.02). By the SCORAD, significant interobserver variation was found in assessing the severity of edema/population (P = 0.04), erythema (P = 0.04), and excoriations (P = 0.01). No significant interobserver variation was found in assessing the extent of AD. The mean difference and the limits of agreement between the SSS and the SCORAD were -4.17 +/- 9.52. kappa between the SSS and the BCSS was 0.21 (95% CI 0.09-0.33), and kappa between the SCORAD and the BCSS was 0.38 (95% CI 0.26-0.51). We found good agreement between observers assessing the overall severity of AD in the lower and higher scoring rates by the SSS and the SCORAD, and excellent agreement by the BCSS. Significant interobserver variation was found on the isolated intensity items scales, excoriations, edema/population, and erythema. We found poor agreement between the three scoring systems in assessing the overall severity of AD, indicating that the SSS, the SCORAD, and the BCSS cannot be used interchangeably to assess the overall severity of AD.

Entities:  

Mesh:

Year:  1997        PMID: 9298180     DOI: 10.1111/j.1398-9995.1997.tb01255.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  10 in total

Review 1.  Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis.

Authors:  Lawrence F Eichenfield; Wynnis L Tom; Sarah L Chamlin; Steven R Feldman; Jon M Hanifin; Eric L Simpson; Timothy G Berger; James N Bergman; David E Cohen; Kevin D Cooper; Kelly M Cordoro; Dawn M Davis; Alfons Krol; David J Margolis; Amy S Paller; Kathryn Schwarzenberger; Robert A Silverman; Hywel C Williams; Craig A Elmets; Julie Block; Christopher G Harrod; Wendy Smith Begolka; Robert Sidbury
Journal:  J Am Acad Dermatol       Date:  2013-11-27       Impact factor: 11.527

2.  Asthma in patients with atopic dermatitis.

Authors:  Z Pourpak; H Mozaffari; M Gharagozlou; Z Daneshmandi; M Moin
Journal:  Indian J Pediatr       Date:  2008-02       Impact factor: 1.967

3.  In Vitro Induction of Allergen-Specific Interleukin-10-Producing Regulatory B Cell Responses by Interferon-γ in Non-Immunoglobulin E-Mediated Milk Allergy.

Authors:  Soo Jin Lee; Geunwoong Noh; Jae Ho Lee
Journal:  Allergy Asthma Immunol Res       Date:  2012-09-27       Impact factor: 5.764

Review 4.  Health outcome measures in atopic dermatitis: a systematic review of trends in disease severity and quality-of-life instruments 1985-2010.

Authors:  Balvinder Rehal; April W Armstrong; April Armstrong
Journal:  PLoS One       Date:  2011-04-13       Impact factor: 3.240

5.  Immunotherapy using Histobulin in atopic dermatitis.

Authors:  Geunwoong Noh
Journal:  Clin Case Rep       Date:  2020-11-11

6.  Gingival Crevicular Fluid Zinc- and Aspartyl-Binding Protease Profile of Individuals with Moderate/Severe Atopic Dermatitis.

Authors:  Fernando Valenzuela; Javier Fernández; Marcela Aroca; Constanza Jiménez; Daniela Albers; Marcela Hernández; Alejandra Fernández
Journal:  Biomolecules       Date:  2020-11-26

7.  The RoScan Thermal 3D Body Scanning System: Medical Applicability and Benefits for Unobtrusive Sensing and Objective Diagnosis.

Authors:  Adam Chromy; Ludek Zalud
Journal:  Sensors (Basel)       Date:  2020-11-20       Impact factor: 3.576

8.  Serum mucosa-associated epithelial chemokine in atopic dermatitis: a specific marker for severity.

Authors:  M H M Ezzat; K Y Shaheen
Journal:  Indian J Dermatol       Date:  2009-07       Impact factor: 1.494

Review 9.  Treatment of eczema.

Authors:  Christopher Chang; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2007-12       Impact factor: 10.817

10.  Differences in Psychometric Properties of Clinician- and Patient-Reported Outcome Measures for Atopic Dermatitis by Race and Skin Tone: A Systematic Review.

Authors:  Trisha Kaundinya; Uros Rakita; Armaan Guraya; Donna Maria Abboud; Emily Croce; Jacob P Thyssen; Andrew Alexis; Jonathan I Silverberg
Journal:  J Invest Dermatol       Date:  2021-08-02       Impact factor: 8.551

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.